Helus’ DMT psychedelic touts antidepressant potential in Phase IIa study
Helus Pharma’s psychedelic compound, SPL026, has demonstrated its potential to treat major depressive disorder (MDD) in a mid-stage study. During a Phase IIa trial (NCT04673383), 34 patients with moderate-to-severe MDD were randomised to receive either a …